Skip to content
Research Article Open access CC BY 4.0

A New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate): An Alternative to Carbapenems for the Management of Intensive Care Unit Infection

Sachin Verma

Microbiology Research Journal International · pp. 1–9 · Published 14 Mar 2016

10.9734/BMRJ/2016/23625

Abstract

Aims: Carbapenem resistant bacterial infections have limited treatment options and are associated with high mortality. Here we present a retrospective analysis of treatment and outcome for ICU patients suffering from moderate to severe urinary tract infection (UTI), lower respiratory tract infection (LRTI) and intra-abdominal  infections (IAI) to assess the efficacy of novel antibiotic adjuvant entity (AAE); ceftriaxone + sulbactam + disodium edetate, as an effective alternative for carbapenems in critically ill patients. Materials and Methods: A retrospective study was conducted to evaluate efficacy of AAE in 84 patients showing sensitivity to AAE with UTI, LRTI and IAI treated at IVY hospital, Mohali, India between January 2013 to November 2014. The antibiotic therapy was initiated empirically and continued based on the results of the microbiological susceptibility testing and clinical outcome. Results: 64 (76.19%), patients were diagnosed with single-organism infections, among which, 14 (16.16%) bacteria were resistant to meropenem and all the bacteria were susceptible to AAE. Empirical meropenem treatment was given to 25 patients, of which 18 (72%) patients achieved clinical success. 24 (75%) patients of 32 patients treated with AAE, achieved clinical success and the remaining 8 patients were cured when colistin was given with AAE. 20 (23.80%), patients were diagnosed with polymicrobial infections. Among 20 polymicrobial infectious patients, bacterial samples of 12 patients showed sensitivity towards AAE and meropenem, where as the remaining 8 (40%) samples showed intermediate susceptibility towards both cabapenem and AAE. 9 (45%) patients were cured with AAE, while the remaining 11 patients were cured with AAE and colistin combination therapy. Conclusion: From the above study, it can be concluded that patients experience similar rates of clinical response in carbapenem susceptible cases and in some cases where patients failed to respond to carbapenem therapy but responded to AAE treatment. Hence, AAE can be used as an alternative to carbapenems in the treatment of moderate and severe infections caused by Gram negative organisms.

Ceftriaxone/sulbactam-EDTA intra-abdominal infections lower respiratory tract infections retrospective study urinary tract infections.

References (32)

  1. 1 Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 [DOI]
  2. 2 Novel Carbapenem-Hydrolyzing β-Lactamase, KPC-1, from a Carbapenem-Resistant Strain of Klebsiella pneumoniae [DOI]
  3. 3 Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive Therapies [DOI]
  4. 4 Comparative Review of the Carbapenems [DOI]
  5. 5 Transferable imipenem resistance in Pseudomonas aeruginosa [DOI]
  6. 6 Predictors of Carbapenem-Resistant Klebsiella pneumoniae Acquisition among Hospitalized Adults and Effect of Acquisition on Mortality [DOI]
  7. 7 Klebsiella pneumoniae AcrAB Efflux Pump Contributes to Antimicrobial Resistance and Virulence [DOI]
  8. 8 Interplay of Efflux System, ampC , and oprD Expression in Carbapenem Resistance of Pseudomonas aeruginosa Clinical Isolates [DOI]
  9. 9 Of Pseudomonas, porins, pumps and carbapenems [DOI]
  10. 10 Molecular Epidemiology and Mechanisms of Carbapenem Resistance in Pseudomonas aeruginosa [DOI]
  11. 11 Discovery research: the scientific challenge of finding new antibiotics [DOI]
  12. 12 Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts [DOI]
  13. 13 New Delhi Metallo-beta lactamase (NDM-1) in Enterobacteriaceae: treatment options with carbapenems compromised.
  14. 14 Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial [DOI]
  15. 15 Newer antibacterial drugs for a new century [DOI]
  16. 16 Emerging resistance to carbapenems in a tertiary care hospital in north India.
  17. 17 Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India [DOI]
  18. 18 Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China [DOI]
  19. 19 A Study on Infections Caused By Metallo Beta Lactamase Producing Gram Negative Bacteria in Intensive Care Unit Patients [DOI]
  20. 20 Rising Antimicrobial Resistance of Pseudomonas aeruginosa Isolated from Clinical Specimens in India [DOI]
  21. 21 Rapid Detection of Klebsiella pneumoniae Carbapenemase Genes in Enterobacteriaceae Directly From Blood Culture Bottles by Real-Time PCR [DOI]
  22. 22 A Novel Approach to Combat Acquired Multiple Resistance in Escherichia coli by using EDTA as Efflux Pump Inhibitor [DOI]
  23. 23 Carbapenems in Pediatrics [DOI]
  24. 24 Carbapenem Resistance among Enterobacter Species in a Tertiary Care Hospital in Central India [DOI]
  25. 25 First Identification and Characterization of an AdeABC-Like Efflux Pump in Acinetobacter Genomospecies 13TU [DOI]
  26. 26 Waging War Against Extended Spectrum Beta Lactamase and Metallobetalactamase Producing Pathogens- Novel Adjuvant Antimicrobial Agent Cse1034- An Extended Hope [DOI]
  27. 27 Role of CSE1034 in Escherichia coli Biofilm Destruction [DOI]
  28. 28 A Combination Strategy of Ceftriaxone, Sulbactam and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A Retrospective, Observational Study in Indian Tertiary Care Hospital [DOI]
  29. 29 Alternative empiric therapy to carbapenems in management of drug resistant gram negative pathogens: a new way to spare carbapenems [DOI]
  30. 30 Ethylenediaminetetraacetic acid: A non antibiotic adjuvant enhancing Pseudomonas aeruginosa susceptibility [DOI]
  31. 31 Sulbactomax prevents antimicrobial resistance development byinhibition of conjugal transfer of F plasmids
  32. 32 Appropriate use of the carbapenems.

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

26

Page views

0

PDF downloads

9

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.